Compare Southwest Airlines Co (LUV) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs 10X Genomics Inc — how do they compare? Southwest Airlines Co trades at $41.4 (market cap $20.41B), while 10X Genomics Inc trades at $79.4 (market cap $9.92B). The key difference: Southwest Airlines Co is far larger — about 2.1× 10X Genomics Inc's market cap, and Southwest Airlines Co pays a 1.73% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and 10X Genomics Inc for 92 Days on average.
| LUV | TXG | |
|---|---|---|
Market Cap | $20.41B | $9.92B |
Volume | 4,706,365 | 9,372,166 |
Sector | Industrials | Health |
52-Week High | $54.80 | $97.74 |
52-Week Low | $29.67 | $11.48 |
Typical Hold Time | 65 Days | 92 Days |
Enterprise Value | $23.51B | $9.44B |
Dividend Yield | 1.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.36, down 2.57% with a bearish technical signal. The company shows mixed fundamentals with a P/E of 26.08 and net margin of 2.78%, while recent earnings beat expectations in Q2 2026. Cash flow trends improved significantly in 2026 projections. Analyst consensus is divided with 42% buy ratings and a $49.61 price target representing 20% upside potential.
LUV's transformation initiatives show promise with projected $2 billion EBIT from new fare structures, though high fuel costs and competitive pressures remain risks. The stock offers value with P/S of 0.73 and strong revenue growth outlook, but requires monitoring of Q3 2026 earnings due October 22 for confirmation of the turnaround trajectory.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
